Peptide Comparison

GLP-1 Agonists vs Tirzepatide

A detailed comparison to help you understand the differences and choose the right peptide for your research.

GL

GLP-1 Agonists

Metabolic & Weight Loss
VS
Ti

Tirzepatide

Metabolic & Weight Loss

Semaglutide and tirzepatide represent the two leading options for GLP-1 based weight management. Both are FDA-approved for diabetes and obesity, but tirzepatide has shown superior weight loss results in clinical trials. The key difference is that tirzepatide activates both GIP and GLP-1 receptors, while semaglutide activates only GLP-1.

Quick Comparison

Aspect
GLP-1 Agonists
Tirzepatide
Mechanism
GLP-1 receptor agonist only
Dual GIP + GLP-1 receptor agonist
Weight Loss
~15-17% average in trials
~20-25% average in trials
A1c Reduction
~1.5-2.0%
~2.0-2.5%
Brand Names
Ozempic, Wegovy, Rybelsus
Mounjaro, Zepbound
Dosing
Weekly injection (up to 2.4mg)
Weekly injection (up to 15mg)
FDA Approval
2017 (diabetes), 2021 (obesity)
2022 (diabetes), 2023 (obesity)
Time on Market
Longer track record
Newer, less long-term data
Cost
Similar price range
Similar price range

Key Similarities

  • Both are once-weekly injections
  • Both FDA-approved for diabetes and obesity
  • Both reduce appetite significantly
  • Both cause similar GI side effects (nausea, etc.)
  • Both require slow dose titration
  • Both show cardiovascular benefits
  • Both cause weight regain after stopping

Key Differences

  • Tirzepatide adds GIP activation
  • Tirzepatide shows ~5-10% more weight loss
  • Semaglutide has longer market history
  • Tirzepatide may have slightly better glucose control
  • Semaglutide available in oral form (Rybelsus)
  • More long-term safety data for semaglutide
  • Tirzepatide dosing goes to 15mg vs 2.4mg

When to Choose Each

Choose GLP-1 Agonists

Choose semaglutide if you want a well-established option with the longest safety track record, need an oral option (Rybelsus), or achieve satisfactory results with the standard GLP-1 approach. Still highly effective with 15-17% weight loss.

Choose Tirzepatide

Choose tirzepatide if maximizing weight loss is the priority (up to 25%), you want the latest technology (dual agonist), or haven't achieved desired results with GLP-1 alone. The most effective approved weight loss medication.

Can You Stack Them?

These should NOT be combined—they work on overlapping pathways and combining would increase side effects without proportional benefits. Choose one or the other based on your goals and provider recommendation.

Frequently Asked Questions

Tirzepatide consistently shows greater weight loss in head-to-head comparisons—approximately 20-25% vs 15-17% for semaglutide. The dual GIP/GLP-1 action appears to be more effective.
Side effects are very similar—nausea, vomiting, diarrhea, constipation. Both require slow titration to minimize GI effects. Neither clearly has fewer side effects than the other.
Yes, switching is possible under medical supervision. Some who don't reach goals on semaglutide switch to tirzepatide. Dosing adjustments are needed during transition.

References

  1. Wilding JPH, et al. "STEP trials semaglutide." NEJM, 2021. PMID: 33567185
  2. Jastreboff AM, et al. "SURMOUNT tirzepatide." NEJM, 2022. PMID: 35658024

Get the Complete Comparison Guide

Download our detailed comparison charts and decision framework.